These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Failure to launch commercially-approved mesenchymal stromal cell therapies: what's the path forward? Proceedings of the International Society for Cell & Gene Therapy (ISCT) Annual Meeting Roundtable held in May 2023, Palais des Congrès de Paris, Organized by the ISCT MSC Scientific Committee. Robb KP; Galipeau J; Shi Y; Schuster M; Martin I; Viswanathan S Cytotherapy; 2024 May; 26(5):413-417. PubMed ID: 37804284 [TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory effects of extracellular vesicles from mesenchymal stromal cells: Implication for therapeutic approach in autoimmune diseases. Liao HJ; Hsu PN Kaohsiung J Med Sci; 2024 Jun; 40(6):520-529. PubMed ID: 38712483 [TBL] [Abstract][Full Text] [Related]
4. Interactions of mesenchymal stromal/stem cells and immune cells following MSC-based therapeutic approaches in rheumatoid arthritis. Dehnavi S; Sadeghi M; Tavakol Afshari J; Mohammadi M Cell Immunol; 2023; 393-394():104771. PubMed ID: 37783061 [TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of preclinical studies of mesenchymal stromal cells to treat rheumatoid arthritis. Liu L; Wong CW; Han M; Farhoodi HP; Liu G; Liu Y; Liao W; Zhao W EBioMedicine; 2019 Sep; 47():563-577. PubMed ID: 31501076 [TBL] [Abstract][Full Text] [Related]
6. Mesenchymal Stem Cells-Involved Strategies for Rheumatoid Arthritis Therapy. Li C; Sun Y; Xu W; Chang F; Wang Y; Ding J Adv Sci (Weinh); 2024 Jun; 11(24):e2305116. PubMed ID: 38477559 [TBL] [Abstract][Full Text] [Related]
7. Serum metabolomics reveals the effectiveness of human placental mesenchymal stem cell therapy for Crohn's disease. Wang X; Shang D; Chen J; Cheng S; Chen D; Zhang Z; Liu C; Yu J; Cao H; Li L; Li L Talanta; 2024 Sep; 277():126442. PubMed ID: 38897006 [TBL] [Abstract][Full Text] [Related]
8. Cell-Based Therapy and Genome Editing as Emerging Therapeutic Approaches to Treat Rheumatoid Arthritis. Chasov V; Ganeeva I; Zmievskaya E; Davletshin D; Gilyazova E; Valiullina A; Bulatov E Cells; 2024 Jul; 13(15):. PubMed ID: 39120313 [TBL] [Abstract][Full Text] [Related]
9. Patient engagement and satisfaction with early phase cell therapy clinical trials at a tertiary inflammatory bowel disease center. Obi M; Adams A; Vandenbossche A; Otero Pineiro A; Lightner AL Stem Cell Reports; 2024 Apr; 19(4):435-442. PubMed ID: 38552633 [TBL] [Abstract][Full Text] [Related]
11. Update on mesenchymal stem cell-based therapy in lupus and scleroderma. Cras A; Farge D; Carmoi T; Lataillade JJ; Wang DD; Sun L Arthritis Res Ther; 2015 Nov; 17():301. PubMed ID: 26525582 [TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stromal cells and autoimmunity. Pistoia V; Raffaghello L Int Immunol; 2017 Feb; 29(2):49-58. PubMed ID: 28338763 [TBL] [Abstract][Full Text] [Related]
13. Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Dave M; Mehta K; Luther J; Baruah A; Dietz AB; Faubion WA Inflamm Bowel Dis; 2015 Nov; 21(11):2696-707. PubMed ID: 26230863 [TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells and adaptive immune responses. Cao W; Cao K; Cao J; Wang Y; Shi Y Immunol Lett; 2015 Dec; 168(2):147-53. PubMed ID: 26073566 [TBL] [Abstract][Full Text] [Related]
15. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Bluestone JA; Buckner JH; Fitch M; Gitelman SE; Gupta S; Hellerstein MK; Herold KC; Lares A; Lee MR; Li K; Liu W; Long SA; Masiello LM; Nguyen V; Putnam AL; Rieck M; Sayre PH; Tang Q Sci Transl Med; 2015 Nov; 7(315):315ra189. PubMed ID: 26606968 [TBL] [Abstract][Full Text] [Related]
16. Clinical Trials With Mesenchymal Stem Cells: An Update. Squillaro T; Peluso G; Galderisi U Cell Transplant; 2016; 25(5):829-48. PubMed ID: 26423725 [TBL] [Abstract][Full Text] [Related]